Overview

Pain Therapeutics Market Overview:

FutureWise Market Research has instantiated a report that provides an intricate analysis of Pain Therapeutics Market trend that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Pain Therapeutics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Pain Therapeutics Market:
• Abbvie INc.
• Acelrx Pharmaceuticals Inc.
• Adynnx
• Alder Biopharmaceuticals Inc.
• Allergan PLC
• Astellas Pharmaceuticals Inc.
• Axsome Therapeutics Inc.
• Biohaven Pharmaceuticals Holding Company Ltd.
• Biogen Inc.
• Calchan Ltd.
• Centrexion Therapeutics Corp.
• Daiichi Sankyo Company Ltd.
• Durect Corporation
• Egalet Corporation
• Eli Lilly & Company
• Galapagos NV
• Genentech Inc.
• Novartis International AG
• Pfizer Inc.
• TEVA Pharmaceuticals
• Trevena Inc.
• Vertex Pharmaceuticals Inc.
• Viromed Co. Ltd.
• Wex Pharmaceuticals Inc.
• Xenon Pharmaceuticals Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Pain Therapeutics Market Segmentation:
By Disease Type
• Postoperative Pain
• Neuropathic Pain
• Fibromyalgia
• Arthritic Pain
• Migraine
• Cancer Pain

By End User
• Hospitals
• Clinics
• Others

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Pain Therapeutics Market By Disease Type, By End User and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customisation offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Pain Therapeutics Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Product Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Pain Therapeutics Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Product Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Product Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Pain Therapeutics Market, By Disease Type Historical Analysis and Forecast 2020-2027 (USD Million)
  7.1.  Postoperative Pain
  7.2. Neuropathic Pain
  7.3. Fibromyalgia
  7.4. Arthritic Pain
  7.5. Migraine
  7.6. Cancer Pain

8. Global Pain Therapeutics Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
  8.1. Hospitals
  8.2. Clinics
  8.3. Others

9. North America Pain Therapeutics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
  9.1. Introduction
  9.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
       9.2.1. U.S.A
       9.2.2. Canada
       9.2.3. Mexico
  9.3. Market Size (USD Million) Forecast for North America 2020-2027

10. Latin America Pain Therapeutics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   10.1. Introduction
   10.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         10.2.1. Brazil
         10.2.2. Venezuela
         10.2.3. Argentina
         10.2.4. Rest of Latin America
   10.3. Market Size (USD Million) Forecast for Latin America 2020-2027

11. Europe Pain Therapeutics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         11.2.1. Germany
         11.2.2. U.K        
         11.2.3. France
         11.2.4. Italy
         11.2.5. Spain
         11.2.6. Russia
         11.2.7. Poland
         11.2.8. Rest of Europe
   11.3. Market Size (USD Million) Forecast for Europe 2020-2027

12. Asia Pacific Pain Therapeutics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   12.1. Introduction
   12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         12.2.1. Japan
         12.2.2. China
         12.2.3. India
         12.2.4. Australia and New Zealand
         12.2.5. ASEAN
         12.2.6. Rest of Asia Pacific
   12.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

13. Middle East and Africa Pain Therapeutics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
         13.2.1. Saudi Arabia
         13.2.2. UAE
         13.2.3. South Africa
         13.2.4. Egypt
   13.3. Market Size (USD Million) Forecast for MEA 2020-2027

14. Market Share Analysis and Competitive Landscape  
   14.1. Global Landscape - Key Players, Revenue and Presence
   14.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   14.3. Global Emerging Companies
   14.4. North America - Market Share Analysis and Key Regional Players
   14.5. Europe - Market Share Analysis and Key Regional Players
   14.6. Asia Pacific - Market Share Analysis and Key Regional Players
   14.7. Global Key Player - Growth Matrix

15. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
  15.1. Abbvie INc.
         15.1.1. Company Overview
         15.1.2. Product Portfolio
         15.1.3. SWOT Analysis
         15.1.4. Financial Overview
         15.1.5. Strategic Overview
 15.2. Acelrx Pharmaceuticals Inc.
         15.2.1. Company Overview
         15.2.2. Product Portfolio
         15.2.3. SWOT Analysis
         15.2.4. Financial Overview
         15.2.5. Strategic Overview
 15.3. Adynnx
         15.3.1. Company Overview
         15.3.2. Product Portfolio
         15.3.3. SWOT Analysis
         15.3.4. Financial Overview
         15.3.5. Strategic Overview
 15.4. Alder Biopharmaceuticals Inc..
         15.4.1. Company Overview
         15.4.2. Product Portfolio
         15.4.3. SWOT Analysis
         15.4.4. Financial Overview
         15.4.5. Strategic Overview
 15.5. Allergan PLC
         15.5.1. Company Overview
         15.5.2. Product Portfolio
         15.5.3. SWOT Analysis
         15.5.4. Financial Overview
         15.5.5. Strategic Overview          
15.6.  Astellas Pharmaceuticals Inc.
         15.6.1. Company Overview
         15.6.2. Product Portfolio
         15.6.3. SWOT Analysis
         15.6.4. Financial Overview
         15.6.5. Strategic Overview
  15.7.  Axsome Therapeutics Inc.
         15.7.1. Company Overview
         15.7.2. Product Portfolio
         15.7.3. SWOT Analysis
         15.7.4. Financial Overview
         15.7.5. Strategic Overview
   15.8.  Biohaven Pharmaceuticals Holding Company Ltd.
         15.8.1. Company Overview
         15.8.2. Product Portfolio
         15.8.3. SWOT Analysis
         15.8.4. Financial Overview
         15.8.5. Strategic Overview
   15.9. Biogen Inc.
         15.9.1. Company Overview
         15.9.2. Product Portfolio
         15.9.3. SWOT Analysis
         15.9.4. Financial Overview
         15.9.5. Strategic Overview
   15.10. Calchan Ltd.
         15.10.1. Company Overview
         15.10.2. Product Portfolio
         15.10.3. SWOT Analysis
         15.10.4. Financial Overview
         15.10.5. Strategic Overview
   15.11. Centrexion Therapeutics Corp.
         15.11.1. Company Overview
         15.11.2. Product Portfolio
         15.11.3. SWOT Analysis
         15.11.4. Financial Overview
         15.11.5. Strategic Overview
   15.12. Daiichi Sankyo Company Ltd.
         15.12.1. Company Overview
         15.12.2. Product Portfolio
         15.12.3. SWOT Analysis
         15.12.4. Financial Overview
         15.12.5. Strategic Overview
   15.13.  Durect Corporation
         15.13.1. Company Overview
         15.13.2. Product Portfolio
         15.13.3. SWOT Analysis
         15.13.4. Financial Overview
         15.13.5. Strategic Overview
   15.14. Egalet Corporation
         15.14.1. Company Overview
         15.14.2. Product Portfolio
         15.14.3. SWOT Analysis
         15.14.4. Financial Overview
         15.14.5. Strategic Overview
   15.15. Eli Lilly & Company
         15.15.1. Company Overview
         15.15.2. Product Portfolio
         15.15.3. SWOT Analysis
         15.15.4. Financial Overview
         15.15.5. Strategic Overview                                                                                                                                                                                           15.16. Galapagos NV
         15.16.1. Company Overview
         15.16.2. Product Portfolio
         15.16.3. SWOT Analysis
         15.16.4. Financial Overview
         15.16.5. Strategic Overview
 15.17. Genentech Inc.
         15.17.1. Company Overview
         15.17.2. Product Portfolio
         15.17.3. SWOT Analysis
         15.17.4. Financial Overview
         15.17.5. Strategic Overview                                                                                                                                                                                            15.18. Novartis International AG
         15.18.1. Company Overview
         15.18.2. Product Portfolio
         15.18.3. SWOT Analysis
         15.18.4. Financial Overview
         15.18.5. Strategic Overview                                                                                                                                                                                            15.19. Pfizer Inc.
         15.19.1. Company Overview
         15.19.2. Product Portfolio
         15.19.3. SWOT Analysis
         15.19.4. Financial Overview
         15.19.5. Strategic Overview
15.20. TEVA Pharmaceuticals
         15.20.1. Company Overview
         15.20.2. Product Portfolio
         15.20.3. SWOT Analysis
         15.20.4. Financial Overview
         15.20.5. Strategic Overview
15.21. Trevena Inc.
         15.21.1. Company Overview
         15.21.2. Product Portfolio
         15.21.3. SWOT Analysis
         15.21.4. Financial Overview
         15.21.5. Strategic Overview                                                                                                                                                                                     15.22. Vertex Pharmaceuticals Inc.
         15.22.1. Company Overview
         15.22.2. Product Portfolio
         15.22.3. SWOT Analysis
         15.22.4. Financial Overview
         15.22.5. Strategic Overview
  15.23. Viromed Co. Ltd.
         15.23.1. Company Overview
         15.23.2. Product Portfolio
         15.23.3. SWOT Analysis
         15.23.4. Financial Overview
         15.23.5. Strategic Overview
  15.24. Wex Pharmaceuticals Inc.
         15.24.1. Company Overview
         15.24.2. Product Portfolio
         15.24.3. SWOT Analysis
         15.24.4. Financial Overview
         15.24.5. Strategic Overview
    15.25. Xenon Pharmaceuticals Inc.
         15.25.1. Company Overview
         15.25.2. Product Portfolio
         15.25.3. SWOT Analysis
         15.25.4. Financial Overview
         15.25.5. Strategic Overview

16. Pre and Post COVID-19 Impact
   16.1. Positive influence on the healthcare industry
   16.2. The financial disruption of the healthcare sector
   16.3. Impact of COVID-19 on emerging companies
   16.4. Significant mandates in the healthcare regulations initiated by administrations
   16.5. The overall economic slowdown of the developing and developed nations

17. FutureWise SME Key Takeaway Points for Client

Tables

Figures